Are Wall Street Analysts Bullish on Incyte Stock?

Delaware-based Incyte Corporation (INCY) focuses on the discovery, development, and commercialization of therapeutics for hematology, oncology, and inflammation & autoimmunity conditions. Valued at $13.6 billion by market cap, Incyte’s expertise in medicinal chemistry and biology has enabled it to create a diversified portfolio of marketed products and clinical candidates.

The biotech major has slightly lagged behind the broader market over the past year. INCY stock has gained 21.6% over the past 52 weeks and nearly 2% on a YTD basis, compared to the S&P 500 Index’s ($SPX) 22.3% surge over the past year and 4% gains in 2025.